The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.”
Reps. Abigail Spanberger (D-Va.) and David McKinley (R-W.Va.) offered the statement as an amendment to a seven-bill fiscal year 2022 spending package that includes funding for the 340B program and other health care programs.
The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers' unlawful actions that have resulted in overcharges to 340B covered entities.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
